From the Research
Patients taking Entresto (sacubitril/valsartan) typically begin to experience noticeable improvements in heart failure symptoms within 2-4 weeks after starting the medication, though some may notice changes sooner, as supported by the most recent study 1. The full benefits of Entresto often develop gradually over 3-6 months of consistent use. The medication works by enhancing beneficial neurohormonal systems while blocking harmful ones, specifically inhibiting neprilysin (which breaks down beneficial natriuretic peptides) and blocking angiotensin II receptors. This dual action reduces strain on the heart, improves cardiac function, and decreases fluid retention. Some key points to consider when taking Entresto include:
- Starting at a lower dose (usually 24/26 mg or 49/51 mg twice daily) and gradually increasing to the target dose (97/103 mg twice daily) as tolerated 2
- Common side effects include low blood pressure, dizziness, and increased potassium levels 1
- Patients should report persistent side effects to their healthcare provider but should not stop taking Entresto suddenly without medical guidance
- The medication has been shown to be effective in patients with heart failure with reduced ejection fraction, with improvements in symptoms, quality of life, and cardiac function 1, 3 It's also important to note that Entresto can be used in patients with end-stage renal insufficiency, as shown in a case study where a patient undergoing hemodialysis was able to tolerate a moderate dose of 49/51 mg twice daily 4. However, the most recent and highest quality study 1 provides the most relevant information for guiding clinical practice. Overall, Entresto is a valuable treatment option for patients with heart failure, and its benefits can be seen within a few weeks to months of starting the medication.